Clinical activity of cefepime in severe infections

Clinical Microbiology and Infection

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Beaucaire, Gilles ^a  

^a UNIV LILLE   (France)

Author keywords

Cefepime; Nosocomial infections; Severe infections

Indexed keywords

CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; BACTERIAL INFECTION; CONFERENCE PAPER; FEBRILE NEUTROPENIA; HOSPITAL INFECTION; INTENSIVE CARE UNIT; PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

BACTERIA (MICROORGANISMS);

EID: 0033041349     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00718.x     Document Type: Conference Paper

References (20)

1. Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY 28142, with other broad spectrum β-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207-16.
2. Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drug 1994; 47(suppl 3): 471-505.
3. Thornsberry C, Yee YC. Comparative activity of eight antimicrobial agents against clinical bacteria isolates from the United States, measured by two methods. Am J Med 1996; 100(suppl 6A): 26S-38S.
4. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5 year period. Am J Med 1996; 100(suppl 6A): 13S-19S.
5. Fung-Tomc J, Dougherty TJ, De Orio FJ, Simich-Jacobsom V, Kessler RE. Activity of cefepime against ceftazidime and cefotaxime resistant gram negative bacteria and its relation to β-lactamase levels. Antimicrob Agents Chemother 1989; 33: 498-502.
6. Duval J, Soussy CJ, Acar JF, et al. In vitro antibacterial activity of cefepime: a multicenter study. J Antimicrob Chemother 1993; 32(suppl B): 55-61.
7. Pechère JC, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother 1992; 29: 563-73.
8. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother 1993; 32(suppl B): 75-80.
9. Kieft H, Hoepelman AIM, Rosenberg-Arska M, et al. Clinical evaluation of cefepime in severe bacterial infections and sepsis. Antimicrob Agents Chemother 1993; 38: 415-21.
10. Jonquet O, Micoud M, Jarlier V, et al. Efficacité bactério-clinique du cefepime chez 502 patients ayant une infection sévère: étude nationale multicentrique [abstract 63/P6]. In: Program and abstracts of the 16th Interdisciplinary Meeting on Antiinfectious Chemotherapy, Paris, France. Paris: AORIC, 1996: 115.
11. Gouin F, Papazian L, Martin C, et al. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother 1993; 32(suppl B): 205-14.
12. Beaucaire G, Nicolas MH, Martin C, et al. Etude PHARE. Etude comparative de l'association céfépime-amikacine versus ceftazidime en association avec l'amikacine dans le traitement des pneumonies nosocomiales chez les patients ventilés. Ann Fr Anesth Réanim 1999; 18: 186-95.
13. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543-9.
14. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997; 132: 1294-302.
15. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
16. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-32.
17. Thornberry C, Brown SD, Yee YC, Bouchillon JK, Marler JK, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother 1993; 32(suppl B): 31-53.
18. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997; 24: 41-51.
19. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts G, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704-8.
20. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100(suppl 6A): 83S-9S.